Skip to main content
SpringerLink
Log in

Development of Effective Cancer Vaccine Using Targeting System of Antigen Protein to APCs

  • Research Paper
  • Published:
Pharmaceutical Research Aims and scope Submit manuscript

ABSTRACT

Purpose

To develop a novel cancer vaccine using the targeting system of antigen protein to antigen-presenting cells (APCs) for efficient and safe cancer therapy.

Methods

The novel delivery system was constructed with antigen protein, benzalkonium chloride (BK), and γ-polyglutamic acid (γ-PGA), using ovalbumin (OVA) as a model antigen protein and evaluating its immune induction effects and utilities for cancer vaccine.

Results

BK and γ-PGA enabled encapsulation of OVA and formed stable anionic particles at nanoscale, OVA/BK/γ-PGA complex. Complex was taken up by dendritic cell line DC2.4 cells efficiently. We subcutaneously administered the complex to mice and examined induction of IgGs. The complex induced not only Th2-type immunoglobulins but also Th1-type immunoglobulins. OVA/BK/γ-PGA complex inhibited tumor growth of E.G7 cells expressing OVA regularly; administered OVA/BK/γ-PGA complex completely rejected tumor cells.

Conclusion

The novel vaccine could be platform technology for a cancer vaccine.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

REFERENCES

  1. Tan A, De La Peña H, Seifalian AM. The application of exosomes as a nanoscale cancer vaccine. Int J Nanomed. 2010;5:889–900.

    CAS  Google Scholar 

  2. Andersen MH, Junker N, Ellebaek E, Svane IM, Thor Straten P. Therapeutic cancer vaccines in combination with conventional therapy. J Biomed Biotechnol. 2010;2010(237623):1–10.

    Article  Google Scholar 

  3. Dougan M, Dranoff G. Immune therapy for cancer. Annu Rev Immunol. 2009;27:83–117.

    Article  PubMed  CAS  Google Scholar 

  4. Kyte JA, Trachsel S, Risberg B, thor Straten P, Lislerud K, Gaudernack G. Unconventional cytokine profiles and development of T cell memory in long-term survivors after cancer vaccination. Canc Immunol Immunother. 2009;58(10):1609–26.

    Article  CAS  Google Scholar 

  5. Zimmermann VS, Casati A, Schiering C, Caserta S, Hess Michelini R, Basso V, et al. Tumors hamper the immunogenic competence of CD4+ T cell-directed dendritic cell vaccination. J Immunol. 2007;179(5):2899–909.

    PubMed  CAS  Google Scholar 

  6. McKee AS, Munks MW, Marrack P. How do adjuvants work? Important considerations for new generation adjuvants. Immunity. 2007;27(5):687–90.

    Article  PubMed  CAS  Google Scholar 

  7. Dubensky Jr TW, Reed SG. Adjuvants for cancer vaccines. Semin Immunol. 2010;22(3):155–61.

    Article  PubMed  CAS  Google Scholar 

  8. Asif M, Jenkins KA, Hilton LS, Kimpton WG, Bean AG, Lowenthal JW. Cytokines as adjuvants for avian vaccines. Immunol Cell Biol. 2004;82(6):638–43.

    Article  PubMed  CAS  Google Scholar 

  9. Casella CR, Mitchell TC. Putting endotoxin to work for us: monophosphoryl lipid A as a safe and effective vaccine adjuvant. Cell Mol Life Sci. 2008;65(20):3231–40.

    Article  PubMed  CAS  Google Scholar 

  10. Ulmer JB, Wahren B, Liu MA. Gene-based vaccines: recent technical and clinical advances. Trends Mol Med. 2006;12(5):216–22.

    Article  PubMed  CAS  Google Scholar 

  11. Kurosaki T, Kitahara T, Fumoto S, Nishida K, Nakamura J, Niidome T, et al. Ternary complexes of pDNA, polyethylenimine, and gamma-polyglutamic acid for gene delivery systems. Biomaterials. 2009;30(14):2846–53.

    Article  PubMed  CAS  Google Scholar 

  12. Kurosaki T, Kitahara T, Kawakami S, Nishida K, Nakamura J, Teshima M, et al. The development of a gene vector electrostatically assembled with a polysaccharide capsule. Biomaterials. 2009;30(26):4427–34.

    Article  PubMed  CAS  Google Scholar 

  13. Shuaibu MN, Cherif MS, Kurosaki T, Helegbe GK, Kikuchi M, Yanagi T, et al. Effect of nanoparticle coating on the immunogenicity of plasmid DNA vaccine encoding P. yoelii MSP-1 C-terminal. Vaccine. 2011;29(17):3239–47.

    Article  PubMed  CAS  Google Scholar 

  14. Yoshikawa T, Okada N, Oda A, Matsuo K, Matsuo K, Kayamuro H, et al. Nanoparticles built by self-assembly of amphiphilic gamma-PGA can deliver antigens to antigen-presenting cells with high efficiency: a new tumor-vaccine carrier for eliciting effector T cells. Vaccine. 2008;26(10):1303–13.

    Article  PubMed  CAS  Google Scholar 

  15. Janikashvili N, Larmonier N, Katsanis E. Personalized dendritic cell-based tumor immunotherapy. Immunotherapy. 2010;2(1):57–68.

    Article  PubMed  CAS  Google Scholar 

  16. Palucka K, Ueno H, Fay J, Banchereau J. Dendritic cells and immunity against cancer. J Intern Med. 2011;269(1):64–73.

    Article  PubMed  CAS  Google Scholar 

  17. Neyestani TR, Woodward WD, Hillyer L. Serum levels of Th2-Type immunoglobulins are increased in weanling mice subjected to acute wasting protein-energy malnutrition. Iran J Allergy Asthma Immunol. 2004;3(1):1–6.

    PubMed  Google Scholar 

  18. Prodhomme EJ, Tutt AL, Glennie MJ, Bugg TD. Multivalent conjugates of poly-gamma-D-glutamic acid from Bacillus licheniformis with antibody F(ab′) and glycopeptide ligands. Bioconjug Chem. 2003;14(6):1148–55.

    Article  PubMed  CAS  Google Scholar 

  19. Ye H, Jin L, Hu R, Yi Z, Li J, Wu Y, et al. Poly(gamma, L-glutamic acid)-cisplatin conjugate effectively inhibits human breast tumor xenografted in nude mice. Biomaterials. 2006;27(35):5958–65.

    Article  PubMed  CAS  Google Scholar 

  20. Marple B, Roland P, Benninger M. Safety review of benzalkonium chloride used as a preservative in intranasal solutions: an overview of conflicting data and opinions. Otolaryngol Head Neck Surg. 2004;130(1):131–41.

    Article  PubMed  Google Scholar 

  21. Liebert MA. Final report on the safety assessment of benzalkonium chloride. Int J Toxicol. 1989;8(4):589–625.

    Article  Google Scholar 

Download references

ACKNOWLEDGMENTS & DISCLOSURES

This study was supported in part by the Uehara Memorial Foundation, the Global COE Program, Nagasaki University, Japan, Grant-in-Aid for JSPS Fellows, and Grant-in-Aid for Scientific Research from Japan Society for the Promotion of Science.

Author information

Authors and Affiliations

  1. Department of Drug Delivery Research Graduate School of Pharmaceutical Sciences, Kyoto University, 46-29 Yoshida-shimoadachi-cho, Sakyo-ku, Kyoto, 606-8501, Japan

    Tomoaki Kurosaki

  2. The Japan Society for the Promotion of Science (JSPS), Chiyoda-ku, Tokyo, 102-8471, Japan

    Tomoaki Kurosaki

  3. Department of Hospital Pharmacy, Nagasaki University Hospital, 1-7-1 Sakamoto, Nagasaki, 852-8501, Japan

    Takashi Kitahara, Tadahiro Nakamura, Yukinobu Kodama, Hiroo Nakagawa, Norihide Higuchi & Hitoshi Sasaki

  4. Graduate School of Biomedical Sciences, Nagasaki University, 1-14 Bunkyo-machi, Nagasaki, 852-8521, Japan

    Koyo Nishida & Shintaro Fumoto

  5. Global COE Program, Nagasaki University, 1-12-4 Sakamoto, Nagasaki, 852-8523, Japan

    Hitoshi Sasaki

Authors
  1. Tomoaki Kurosaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Takashi Kitahara
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tadahiro Nakamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Koyo Nishida
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Shintaro Fumoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yukinobu Kodama
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hiroo Nakagawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Norihide Higuchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Hitoshi Sasaki
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hitoshi Sasaki.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kurosaki, T., Kitahara, T., Nakamura, T. et al. Development of Effective Cancer Vaccine Using Targeting System of Antigen Protein to APCs. Pharm Res 29, 483–489 (2012). https://doi.org/10.1007/s11095-011-0571-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11095-011-0571-x

KEY WORDS

Search

Navigation